Form 6-K — CureVac N.V.: contract with the German federal government to supply mRNA vaccines (April 11, 2022)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of April, 2022, Commission File Number 001-39446. It states that on April 11, 2022 the company issued a press release announcing that it and GSK have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. After a setup period of a maximum of two years, the contract gives the government access to CureVac's manufacturing capacity until 2029, enabling availability of 80 million mRNA-based vaccine doses. The press release is Exhibit 99.1; the information is incorporated into Form F-3, File No. 333-259613.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of April, 2022

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

On April 11, 2022, CureVac N.V. (the “Company”) issued a press release announcing that they and GSK have entered into a contract
with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup
period of a maximum of two years, the contract grants the German federal government access to CureVac’s manufacturing capacity until
2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the pandemic or in future infectious
disease outbreaks.

The information included in this Form 6-K
(including Exhibit 99.1, but excluding the statements of the Company’s Chief Executive Officer and GSK’s President of
Vaccines and Global Health contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s
Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: April 11, 2022

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated April 11, 2022.

File and source

File

SEC_CVAC_6-K_filed2022-04-11_0001104659-22-044659.htm

Size

14,626 bytes

SHA-256

ff3e9183bd80e467adc7f5fe986f7f22798c7455846ea4f737b7fc7955b2b818

Our copy

SEC_CVAC_6-K_filed2022-04-11_0001104659-22-044659.htm

Original

www.sec.gov